|
Apr 15
|
Shah Capital nominates two highly qualified independent director candidates for Novavax
|
|
Apr 15
|
UPDATE 4-Novavax investor Shah Capital pushes for board shakeup
|
|
Apr 13
|
Better Buy: Bluebird Bio Vs. Novavax
|
|
Apr 12
|
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?
|
|
Apr 11
|
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
|
|
Apr 9
|
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
|
|
Apr 3
|
Ex-Pharma Executive and Cousin Admit to Insider Trading of Kodak
|
|
Apr 3
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Apr 2
|
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague
|
|
Apr 1
|
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
|
|
Mar 29
|
Novavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound?
|
|
Mar 27
|
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
|
|
Mar 9
|
1 Beaten-Down Stock That's Still Not Worth Buying
|
|
Mar 7
|
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
|
|
Mar 7
|
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
|
|
Mar 5
|
It’s Time! 3 Failing Biotech Stocks to Sell Right Now
|
|
Mar 5
|
Exit Alert: 3 Overhyped Stocks With Weak Fundamentals
|
|
Mar 4
|
Is Novavax a Buy Now?
|
|
Feb 15
|
Where Will Novavax Be in 10 Years?
|
|
Jan 9
|
3 Turnaround Stocks With 151% to 600% Upside in 2024, According to Select Wall Street Analysts
|